EyeGate Pharma completes Phase II dry eye trial
EyeGate Pharma, a specialty pharmaceutical company, has fully enrolled and completed all follow-up visits for all patients participating in its Phase II safety and efficacy study of EGP-437,
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.
Oxygen Biotherapeutics, a developer of biotechnology products, and Virginia Commonwealth University have signed a memorandum of understanding to establish a federal defense appropriation-funded joint venture focusing on developing